Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03344094 · ClinicalTrials.gov registry record
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 30
- Enrollment target
NCT03344094 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 30 participants.
The verdict
NCT03344094 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.
Interventions
- DRUG ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-02-23 |
| Est. Completion | 2019-04-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03344094
The ClinicalTrials.gov registry entry for NCT03344094 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ocrelizumab is the first listed.
NCT03344094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03344094 about?
NCT03344094 is a clinical study titled "Mechanism of Action of Ocrelizumab in Multiple Sclerosis". Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.
What is the current status of trial NCT03344094?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2018-02-23. Estimated completion is 2019-04-10.
What interventions are being tested in trial NCT03344094?
The interventions under investigation include: ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT03344094?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.